Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Checkpoint Therapeutics Inc (CKPT)

Checkpoint Therapeutics Inc (CKPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,464
  • Shares Outstanding, K 23,526
  • Annual Sales, $ 190 K
  • Annual Income, $ -62,620 K
  • 60-Month Beta 1.00
  • Price/Sales 159.31
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CKPT with:

Options Overview Details

View History
  • Implied Volatility 139.03% ( +5.92%)
  • Historical Volatility 59.32%
  • IV Percentile 54%
  • IV Rank 20.92%
  • IV High 541.48% on 10/02/23
  • IV Low 32.57% on 09/20/23
  • Put/Call Vol Ratio 0.01
  • Today's Volume 353
  • Volume Avg (30-Day) 215
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 10,907
  • Open Int (30-Day) 10,321

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.74
  • Number of Estimates 2
  • High Estimate -0.67
  • Low Estimate -0.80
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.8500 +2.16%
on 03/14/24
2.3550 -19.75%
on 03/06/24
-0.1200 (-5.97%)
since 02/16/24
3-Month
1.6500 +14.55%
on 01/26/24
2.5850 -26.89%
on 01/04/24
+0.0600 (+3.28%)
since 12/18/23
52-Week
1.3000 +45.38%
on 09/26/23
4.2899 -55.94%
on 03/23/23
-1.7500 (-48.08%)
since 03/17/23

Most Recent Stories

More News
10 Penny Stocks with > 1,000% Upside

Rising interest rates, sky-high inflation, and geopolitical concerns have dragged down the S&P 500 (SPX) and NASDAQ Composite (NDX) into bear market territory. While all this sounds rather doom and gloom,...

AMTI : 0.2630 (-14.30%)
ANGN : 10.0000 (+2.04%)
CKPT : 1.8900 (-1.56%)
EFTR : 11.87 (+7.32%)
FRLN : 6.48 (unch)
GLYC : 2.80 (+9.38%)
MGNX : 15.60 (-2.07%)
OCUP : 1.9300 (+1.58%)
PHAS : 0.0701 (-26.21%)
Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma

Objective response rate of 54.8% in patients with locally advanced cSCC, a potential 2nd indication for cosibelimabPreviously met primary endpoint in...

CKPT : 1.8900 (-1.56%)
Checkpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

WALTHAM, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted...

CKPT : 1.8900 (-1.56%)
Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

WALTHAM, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted...

CKPT : 1.8900 (-1.56%)
Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency

Waivers remove requirement to conduct pediatric clinical studies to support cosibelimab marketing authorization applications in Europe...

CKPT : 1.8900 (-1.56%)
Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

Positive top-line results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma announced in January 2022; BLA...

CKPT : 1.8900 (-1.56%)
Checkpoint Therapeutics to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and...

CKPT : 1.8900 (-1.56%)
Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

WALTHAM, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and...

CKPT : 1.8900 (-1.56%)
2 Biotech Stocks That Could Be 10-Baggers in 2022

These two clinical-stage biotechs have major upcoming catalysts that could catapult their shares higher.

AXSM : 72.54 (-3.97%)
CKPT : 1.8900 (-1.56%)
Checkpoint Therapeutics to Participate in the B. Riley Securities’ Virtual Oncology Conference

WALTHAM, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and...

CKPT : 1.8900 (-1.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New...

See More

Key Turning Points

3rd Resistance Point 2.1142
2nd Resistance Point 2.0613
1st Resistance Point 1.9757
Last Price 1.8900
1st Support Level 1.8372
2nd Support Level 1.7843
3rd Support Level 1.6987

See More

52-Week High 4.2899
Fibonacci 61.8% 3.1478
Fibonacci 50% 2.7950
Fibonacci 38.2% 2.4421
Last Price 1.8900
52-Week Low 1.3000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar